NASDAQ:EVGN Evogene (EVGN) Stock Price, News & Analysis $5.14 +0.30 (+6.20%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$4.79▼$5.1450-Day Range$0.59▼$8.2052-Week Range$4.50▼$11.00Volume55,201 shsAverage Volume14,997 shsMarket Capitalization$211.87 millionP/E RatioN/ADividend YieldN/APrice Target$24.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Evogene alerts: Email Address Evogene MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside371.8% Upside$24.25 Price TargetShort InterestHealthy0.01% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.90 out of 5 starsMedical Sector663rd out of 936 stocksAgricultural Chemicals Industry9th out of 11 stocks 3.5 Analyst's Opinion Consensus RatingEvogene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEvogene has received no research coverage in the past 90 days.Read more about Evogene's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.01% of the outstanding shares of Evogene have been sold short.Short Interest Ratio / Days to CoverEvogene has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evogene has recently decreased by 95.03%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEvogene does not currently pay a dividend.Dividend GrowthEvogene does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EVGN. Previous Next 1.8 News and Social Media Coverage News SentimentEvogene has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Evogene this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for EVGN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Evogene to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Evogene insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.40% of the stock of Evogene is held by insiders.Percentage Held by InstitutionsOnly 10.40% of the stock of Evogene is held by institutions.Read more about Evogene's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Evogene is -11.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evogene is -11.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEvogene has a P/B Ratio of 7.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Evogene's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About Evogene Stock (NASDAQ:EVGN)Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.Read More EVGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EVGN Stock News HeadlinesJuly 24 at 11:01 AM | nz.finance.yahoo.comEvogene Ltd. (EVGN.TA)July 23 at 7:56 PM | msn.comEvogene to effect 1-for-10 reverse stock splitJuly 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.July 23 at 8:48 AM | prnewswire.comEvogene Announces Expected Implementation of 1-for-10 Reverse Share SplitJuly 22, 2024 | americanbankingnews.comEvogene (NASDAQ:EVGN) Receives New Coverage from Analysts at StockNews.comJuly 17, 2024 | prnewswire.comICL and Lavie Bio Leverage Artificial Intelligence to Make Significant Advancement in Development of Yield Increasing Bio-StimulantsJuly 2, 2024 | prnewswire.comLavie Bio Announces Commercial Expansion of Yalos™ to Winter WheatJune 25, 2024 | prnewswire.comCasterra Announces an Additional Purchase Order to Supply Castor Seeds to a New African CountryJuly 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.May 23, 2024 | investorplace.comEVGN Stock Earnings: Evogene Beats EPS, Beats Revenue for Q1 2024May 23, 2024 | prnewswire.comBiomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & MelanomaMay 23, 2024 | prnewswire.comEvogene Reports First Quarter 2024 Financial ResultsMay 21, 2024 | prnewswire.comCasterra Announces Additional Agreements with Seed Producers to Meet Existing & Growing Demand for its Elite Castor SeedsMay 9, 2024 | prnewswire.comEvogene Schedules First Quarter 2024 Financial Results ReleaseApril 11, 2024 | prnewswire.comBiomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual MeetingApril 2, 2024 | finance.yahoo.comEvogene and The Kitchen FoodTech Hub by Strauss Group Established Finally Foods Ltd. - Revolutionizing Protein Production in Plants for the Food IndustryMarch 28, 2024 | prnewswire.comEvogene Announces Filing of Annual Report on Form 20-FMarch 20, 2024 | prnewswire.comEvogene Reports Receipt of Nasdaq Minimum Bid Price NotificationSee More Headlines Receive EVGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evogene and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/23/2024Today7/26/2024Next Earnings (Estimated)8/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Agricultural chemicals Sub-IndustryChemicals Current SymbolNASDAQ:EVGN CUSIPN/A CIK1574565 Webwww.evogene.com Phone(728) 931-1900Fax972-8946-6724Employees140Year FoundedN/APrice Target and Rating Average Stock Price Target$24.25 High Stock Price Target$30.00 Low Stock Price Target$18.50 Potential Upside/Downside+371.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,880,000.00 Net Margins-233.66% Pretax Margin-248.19% Return on Equity-70.96% Return on Assets-41.10% Debt Debt-to-Equity RatioN/A Current Ratio5.06 Quick Ratio4.94 Sales & Book Value Annual Sales$5.64 million Price / Sales37.57 Cash FlowN/A Price / Cash FlowN/A Book Value$0.70 per share Price / Book7.34Miscellaneous Outstanding Shares41,220,000Free Float38,166,000Market Cap$211.87 million OptionableOptionable Beta1.40 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Ofer Haviv CPA (Age 58)CEO & President Comp: $390kDr. Nir Arbel (Age 44)Chief Product Officer Comp: $228kDr. Brian Ember (Age 48)Chief Executive Officer of AgPlenus Ltd Comp: $287kDr. Elran Hillel Haber M.B.A. (Age 44)Ph.D., Chief Executive Officer of Biomica Ltd Comp: $302kMr. Amit Noam Capt. res. (Age 42)Chief Executive Officer of Lavie Bio Ltd. Comp: $136kMr. Yaron Eldad (Age 59)Chief Financial Officer Mr. Mark Kapel (Age 47)Chief Technology Officer Comp: $276kRachel Pomerantz GerberHead of Investor RelationsMr. Sassi Masliah (Age 45)Vice President of Corporate Development Comp: $245kMs. Liat Foigel WejgmanVice President of Human ResourcesMore ExecutivesKey CompetitorsChina Green AgricultureNYSE:CGASenesTechNASDAQ:SNESN2OFFNASDAQ:NITOSave FoodsNASDAQ:SVFDCVR PartnersNYSE:UANView All CompetitorsInstitutional OwnershipBNP Paribas Financial MarketsBought 21,500 shares on 5/1/2024Ownership: 0.222%View All Institutional Transactions EVGN Stock Analysis - Frequently Asked Questions How have EVGN shares performed this year? Evogene's stock was trading at $8.40 on January 1st, 2024. Since then, EVGN shares have decreased by 38.8% and is now trading at $5.14. View the best growth stocks for 2024 here. How were Evogene's earnings last quarter? Evogene Ltd. (NASDAQ:EVGN) issued its earnings results on Thursday, May, 23rd. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $4.19 million for the quarter. Evogene had a negative net margin of 233.66% and a negative trailing twelve-month return on equity of 70.96%. When did Evogene's stock split? Evogene shares reverse split on Thursday, July 25th 2024. The 1-10 reverse split was announced on Tuesday, July 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Evogene? Shares of EVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Evogene own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evogene investors own include AbbVie (ABBV), AcelRx Pharmaceuticals (ACRX), Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Energy Transfer (ET), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX). This page (NASDAQ:EVGN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evogene Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
